Today, the CEO of Agile Therapeutics (AGRX), Alfred Altomari, bought shares of AGRX for $38.5K.
Following this transaction Alfred Altomari’s holding in the company was increased by 11.71% to a total of $365K.
See today’s analyst top recommended stocks >>
Currently, Agile Therapeutics has an average volume of 114.1K.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $2.86, reflecting a 88.2% upside. Starting in March 2018, AGRX received 13 Buy ratings in a row. Three different firms, including Guggenheim and Maxim Group, currently also have a Buy rating on the stock.
Alfred Altomari’s trades have generated a -15.5% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
